



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Adalimumab (Powder)

Cat. No.:	HY-P9S0009
CAS No.:	331731-18-1
Target:	Bacterial; TNF Receptor
Pathway:	Anti-infection; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Adalimumab (Powder) is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF- α) ^{[1][2]} .
In Vitro	Treatment of HUVECs with Adalimumab for up to 12 hours shows no adverse effect on their cell viability, even with a 10-fold higher concentration of Adalimumab than used in this study ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	The elimination half-life ($t_{1/2}$) of Adalimumab is long (~20 days) ^[1] . The enriched fluorescent-labelled adalimumab is observed mainly in major Oil red O-positive lesions documenting good tissue penetration of the drug into the atherosclerotic plaque, without background fluorescence of the vessel wall after vehicle control injection into hypercholesterolemic Ldlr ^{-/-} mice ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Ternant D, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. *Br J Clin Pharmacol*. 2015 Feb;79(2):286-97.
- [2]. Oberoi R, et al. Targeting Tumor Necrosis Factor- α with Adalimumab: Effects on Endothelial Activation and Monocyte Adhesion. *PLoS One*. 2016 Jul 28;11(7):e0160145.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA